ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO291

Ophthalmological Safety of Hydroxychloroquine in CKD

Session Information

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 2000 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

Authors

  • Ftouni, Darin, VA Medical Center Malcom Randall, Gainesville, Florida, United States
  • Shukla, Ashutosh M., VA Medical Center Malcom Randall, Gainesville, Florida, United States
  • Joyce, Malea, VA Medical Center Malcom Randall, Gainesville, Florida, United States
  • Pearce, Kailyn, VA Medical Center Malcom Randall, Gainesville, Florida, United States
  • Kavak, Selin, VA Medical Center Malcom Randall, Gainesville, Florida, United States
  • Martinez-Navarro, Wanda, VA Medical Center Malcom Randall, Gainesville, Florida, United States
  • Segal, Mark S., VA Medical Center Malcom Randall, Gainesville, Florida, United States
  • Cheung, Alfred K., University of Utah Health, Salt Lake City, Utah, United States
  • Shah, Sudhir V., University of Arkansas for Medical Sciences College of Medicine, Little Rock, Arkansas, United States
Background

Hydroxychloroquine (HCQ) is routinely used in advanced CKD for rheumatological disease, despite known concerns for its ophthalmological safety in older individuals and patients with CKD. Recently, HCQ has been implicated in therapeutically treating cardiovascular (CV) disease in patients with CKD.

Methods

We report the findings of the planned interim analysis examining the short-term ophthalmological safety of HCQ among all enrolled Veteran participants (n=100) in the Management of CV disease in cKd (MaCK) study, a phase 2b, randomized placebo-controlled trial aimed to examine the impact of HCQ on CV and renal outcomes. Blinded ophthalmological evaluations were done at baseline and at one-year after randomization by measuring visual acuity and evaluating macular health with autofluorescence(AVF), Humphrey’s visual field (HVF), and optical coherence tomography (OCT), when clinically needed.

Results

Across the 100 Veterans aged 71.21±5.92, 95%male with eGFR of 40.04±7.72 and albuminuria of 438.0±784.4 mcg/gm of creatinine, randomized in 1:1 proportion between placebo:HCQ, worsening of visual acuity was similar across both groups (16 vs. 18, p >0.87). Ophthalmological symptoms prompted repeat macular health evaluation in 22 participants on follow-up with no significant difference between abnormalities detected on AVF (2 in each group), HVF (2 vs. 1 participant), and OCT (2 in each group).

Conclusion

Use of HCQ is safe from short-term ophthalmological perspectives among elderly, predominantly male participants with significant CKD.

Funding

  • Veterans Affairs Support